Biomedical Engineering Reference
In-Depth Information
136. Honeywell R et al (2010) Simple and selective method for the determination of various
tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:1059-1068
137. Gotze L et al (2012) Development and clinical application of a LC-MS/MS method for simul-
taneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta
413:143-149
138. Bouchet S et al (2011) Simultaneous determination of nine tyrosine kinase inhibitors by
96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta
412:1060-1067
139. Neeman M et al. (2011) A LC-MS/MS for the assay of verumafenib, bosutinib, gefitinib and
erlotinib in plasma from cancer patients, Master thesis, School of Pharmaceutical Sciences,
University of Geneva and Lausanne, Switzerland
140. Rudin CM et al (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib
toxicity. J Clin Oncol 26:1119-1127
141. Roche S et al (2009) Development of a high-performance liquid chromatographic-mass spec-
trometric method for the determination of cellular levels of the tyrosine kinase inhibitors
lapatinib and dasatinib. J Chromatogr B Analyt Technol Biomed Life Sci 877:3982-3990
142. Hegedus C et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and
ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Br J Pharmacol 158:1153-1164
143. Haouala A et al (2010) SiRNA-mediated knock-down of P-glycoprotein expression reveals
distinct cellular disposition of anticancer tyrosine kinases inhibitors. Drug Metab Lett
4:114-119
144. D'Avolio A et al (2012) HPLC-MS method for the simultaneous quantification of the antileu-
kemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell
(PBMC). J Pharm Biomed Anal 59:109-116
145. Dahmane E et al (2010) An ultra performance liquid chromatography-tandem MS assay for
tamoxifen metabolites profiling in plasma: first evidence of 4ยข-hydroxylated metabolites in
breast cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 878:3402-3414
146. Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov
2:205-213
147. Jordan VC (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast
cancer. Br J Pharmacol 147(Suppl 1):S269-S276
148. Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment
and prevention of breast cancer. Steroids 72:829-842
149. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med
339:1609-1618
150. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer
Trialists' Collaborative Group (1998). Lancet 351:1451-1467
151. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemo-
therapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an
overview of the randomised trials. Lancet 365:1687-1717
152. Goldhirsch A et al (2007) Progress and promise: highlights of the international expert con-
sensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144
153. Goldhirsch A et al (2009) Thresholds for therapies: highlights of the St gallen international
expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319-1329
154. Visvanathan K et al (2009) American society of clinical oncology clinical practice guideline
update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aro-
matase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258
155. Mathew J et al (2009) Neoadjuvant endocrine treatment in primary breast cancer - review of
literature. Breast 18:339-344
156. Chia YH et al (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications
and use as a research tool. Br J Cancer 103:759-764
